Results 331 to 340 of about 289,824 (354)

HIV-Specific Neutralizing Antibodies

2001
Infection with human immunodeficiency virus type 1 (HIV-1) generates cellular and humoral immune responses of various magnitudes to multiple virus-specific antigens. Perhaps the most beneficial B cell response is one that is directed against the surface gp120 and transmembrane gp41 envelope glycoproteins of the virus; both glycoproteins are major ...
openaire   +2 more sources

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Javier Cortés, Giuseppe Curigliano, Paolo Tarantino   +2 more
exaly  

Current treatment and future directions in the management of anal cancer

Ca-A Cancer Journal for Clinicians, 2022
Leila T Tchelebi, Cathy Eng, Craig A Messick   +2 more
exaly  

Modern developments in germline pharmacogenomics for oncology prescribing

Ca-A Cancer Journal for Clinicians, 2022
Natalie M Reizine, Peter H O'donnell
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Neutralizing antibodies revisited [PDF]

Nature Reviews Immunology, 2002
openaire   +1 more source

Avidity in antibody effector functions and biotherapeutic drug design

Nature Reviews Drug Discovery, 2022
Simone C Oostindie, Janine Schuurman, Paul W H I Parren   +2 more
exaly  

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Nature, 2022
Yunlong Cao, Jing Wang, Fanchong Jian
exaly  

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Nature, 2022
M Cyrus Maher, Jennifer K Logue, Elisabetta Cameroni   +2 more
exaly  

Neutralization of interferon by specific antibody

Virology, 1962
Kari Cantell, Kari Cantell, Kurt Paucker, Kurt Paucker   +3 more
openaire   +3 more sources